Margaret Moline

5.8k total citations
140 papers, 3.8k citations indexed

About

Margaret Moline is a scholar working on Experimental and Cognitive Psychology, Cognitive Neuroscience and Endocrine and Autonomic Systems. According to data from OpenAlex, Margaret Moline has authored 140 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Experimental and Cognitive Psychology, 84 papers in Cognitive Neuroscience and 36 papers in Endocrine and Autonomic Systems. Recurrent topics in Margaret Moline's work include Sleep and related disorders (86 papers), Sleep and Wakefulness Research (81 papers) and Circadian rhythm and melatonin (35 papers). Margaret Moline is often cited by papers focused on Sleep and related disorders (86 papers), Sleep and Wakefulness Research (81 papers) and Circadian rhythm and melatonin (35 papers). Margaret Moline collaborates with scholars based in United States, United Kingdom and Japan. Margaret Moline's co-authors include Elliot D. Weitzman, Gary Zammit, Charles A. Czeisler, Janet C. Zimmerman, Rochelle Zak, Lauren Broch, Gleb Filippov, Jane Yardley, Timothy Hsu and Timothy H. Monk and has published in prestigious journals such as Nature, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Margaret Moline

132 papers receiving 3.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Margaret Moline	1.8k	1.5k	1.3k	627	554	140	3.8k
Ka‐Fai Chung	3.0k 1.7×	2.0k 1.3×	1.1k 0.8×	923 1.5×	1.2k 2.1×	182	6.1k
Tetsuo Shimizu	1.3k 0.7×	1.4k 0.9×	1.2k 0.9×	601 1.0×	721 1.3×	175	4.4k
Wing‐Fai Yeung	2.3k 1.3×	1.6k 1.1×	557 0.4×	285 0.5×	683 1.2×	174	4.5k
Kazuo Mishima	2.5k 1.4×	1.9k 1.2×	2.3k 1.7×	885 1.4×	611 1.1×	199	5.1k
Eckart Rüther	1.1k 0.6×	1.0k 0.7×	596 0.5×	881 1.4×	1.5k 2.7×	116	4.8k
Chantal Mérette	3.1k 1.7×	2.7k 1.8×	925 0.7×	406 0.6×	1.4k 2.6×	115	7.0k
Naomi L. Rogers	2.1k 1.2×	1.4k 0.9×	1.3k 1.0×	638 1.0×	385 0.7×	71	3.8k
Giampaolo Perna	2.2k 1.3×	695 0.5×	405 0.3×	400 0.6×	1.7k 3.0×	223	6.1k
Nicole Vogelzangs	1.4k 0.8×	468 0.3×	478 0.4×	1.1k 1.8×	971 1.8×	73	6.9k
Katsuyoshi Mizukami	583 0.3×	1.2k 0.8×	904 0.7×	778 1.2×	649 1.2×	122	3.4k

Countries citing papers authored by Margaret Moline

Since Specialization

Citations

This map shows the geographic impact of Margaret Moline's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret Moline with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret Moline more than expected).

Fields of papers citing papers by Margaret Moline

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret Moline. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret Moline. The network helps show where Margaret Moline may publish in the future.

Co-authorship network of co-authors of Margaret Moline

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret Moline. A scholar is included among the top collaborators of Margaret Moline based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret Moline. Margaret Moline is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mi, Weifeng, Lijun Xu, Jiyang Pan, et al.. (2025). A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial of lemborexant in adults with insomnia disorder. Sleep Medicine. 139. 108722–108722.

Gotfried, Mark H., Sanford Auerbach, Thien Thanh Dang‐Vu, et al.. (2024). Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials. Drugs & Aging. 41(9). 741–752. 6 indexed citations

Krystal, Andrew D., Pierre Blier, Larry Culpepper, et al.. (2024). Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms. Neuropsychopharmacology Reports. 45(1). e12509–e12509. 2 indexed citations

Cheng, Jocelyn Y., Daniel Lorch, Nancy Hall, & Margaret Moline. (2024). Respiratory safety of lemborexant in adult and elderly subjects with moderate‐to‐severe chronic obstructive pulmonary disease. Journal of Sleep Research. 34(2). e14334–e14334. 2 indexed citations

Kushida, Clete A., et al.. (2024). Effect of lemborexant on sleep architecture in participants with insomnia disorder and mild obstructive sleep apnea. Sleep Medicine. 127. 170–177. 5 indexed citations

Kushida, Clete A., et al.. (2023). 0354 Effect of Lemborexant on Sleep Architecture in Subjects with Comorbid Insomnia and Mild Obstructive Sleep Apnea from a Ph 3 Trial. SLEEP. 46(Supplement_1). A157–A157. 1 indexed citations

Moline, Margaret, Shoji Asakura, Ishani Landry, et al.. (2023). The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology. 240(4). 699–711. 15 indexed citations

Cheng, Jocelyn Y., Daniel Lorch, Alan Lowe, et al.. (2023). A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea. Journal of Clinical Sleep Medicine. 20(1). 57–65. 12 indexed citations

Yardley, Jane, et al.. (2023). Relationship Between Daytime Functioning and Fatigue Over 6 Months in Lemborexant-Treated Subjects with Insomnia Disorder (P4-13.002). Neurology. 100(17_supplement_2). 1 indexed citations

10.

Moline, Margaret, et al.. (2023). Commentary on Yue et al. Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis. Sleep Medicine Reviews. 71. 101816–101816. 2 indexed citations

11.

Rawal, Sumit, et al.. (2023). Lemborexant levels in breast milk after single doses in healthy, lactating women. British Journal of Clinical Pharmacology. 90(1). 158–163. 3 indexed citations

12.

Inoue, Yuichi, Naoki Kubota, Michinori Koebis, et al.. (2022). Comparison of the treatment effectiveness between lemborexant and zolpidem tartrate extended-release for insomnia disorder subtypes defined based on polysomnographic findings. Journal of Clinical Sleep Medicine. 19(3). 519–528. 10 indexed citations

13.

Beuckmann, Carsten T., Erik S. Musiek, Takashi Ueno, et al.. (2021). Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer’s Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant. Journal of Alzheimer s Disease. 81(3). 1151–1167. 15 indexed citations

14.

Moline, Margaret, Gary Zammit, Jocelyn Y. Cheng, et al.. (2021). Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. Journal of Clinical Sleep Medicine. 17(6). 1167–1174. 31 indexed citations

15.

Inoue, Yuichi, Takeshi Watanabe, Kohei Ishikawa, et al.. (2021). Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study. Journal of Clinical Sleep Medicine. 17(5). 1067–1074. 6 indexed citations

16.

Ikeda, Satoshi, et al.. (2020). PMH8 EQ-5D Analysis in Patients with Insomnia: Change of Quality of Life in Lemborexant Phase 3 Trial Sunrise 1. Value in Health. 23. S585–S585.

17.

Murphy, Patricia, Dinesh Kumar, Gary Zammit, Russell Rosenberg, & Margaret Moline. (2020). Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening. Journal of Clinical Sleep Medicine. 16(5). 765–773. 49 indexed citations

18.

Vermeeren, Annemiek, Stefan Jongen, Patricia Murphy, et al.. (2018). On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. SLEEP. 42(4). 54 indexed citations

19.

Forsythe, Anna, et al.. (2014). The Effect of Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, and Health Care Resource Use. Value in Health. 17(7). A401–A401. 1 indexed citations

20.

Kahn, D A, et al.. (2001). Major depression during conception and pregnancy: a guide for patients and families.. PubMed. 110–1. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact